PATENT CLAIM ANALYSIS

Application Number: 16074429
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "093210"]

Abstract:
The invention provides a cellular immunotherapy therapy product comprising CAR T cells that are enriched in CD8+ cells. Also provided are methods for making and using the product.

Claim (Index 28):
The method of  claim 22 , wherein the antigen recognition moiety comprises the (i) heavy chain complementarity determining region (CDR)1, (ii) heavy chain CDR2, (iii) heavy chain CDR3, (iv) light chain CDR1, (v) light chain CDR2, and (vi) light chain CDR3 of any one of the amino acid sequences selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 95.0
- Lexical Diversity: 1.15385
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14389677', '15965739', '15965738', '14805193', '16050754']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7719023588515668
- 35 USC 102 Novelty (BERT): 0.5265179284560152
- Combined Prediction Score: 0.7473639158120117
- Mean Citation Score: 334.43033
- Max Citation Score: 346.75323
- Similarity Product: 270.48313456525324

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test